RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Tranzyme Pharma today announced today that the Company will present at the UBS Global Life Sciences Conference in New York, NY on Tuesday, September 21 at 2:30 p.m. ET.

Tranzyme Pharma is a clinical-stage drug development company that discovers and develops novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical needs. The Company's pipeline is derived from its proprietary drug discovery (chemistry) technology, MATCH™, and targets products for gastrointestinal motility and metabolic diseases. For more information, please visit www.tranzyme.com.

CONTACT:

Tranzyme Pharma
Vipin K. Garg, PhD, President and CEO,
919-313-4764, vgarg@tranzyme.com or
Jennifer A. Filbey, PhD, VP, Business Development
256-417-8568, jfilbey@tranzyme.com or
Susan S. Josselyn, Corporate Communications Manager
919-313-4761, sjosselyn@tranzyme.com

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Oncology  Pharmaceutical  Radiology  Diabetes

MEDIA:

Logo